[ad_1]
AstraZeneca has suspended testing of the COVID-19 vaccine it is developing in partnership with the University of Oxford, to investigate the case of a participant who may have suffered a serious adverse reaction.
According to the British company, the suspension of the clinical trials was voluntary, so it is possible to analyze the case. “As part of the ongoing global randomized controlled trials of the Oxford coronavirus vaccine, our review protocol resulted in a vaccination interruption to allow review of safety data,” a company spokesperson told the Financial Times. “.
“This is a routine situation that has to occur whenever there is a potentially unexplained illness in one of the trials, while it is being investigated, ensuring that we maintain the integrity of the tests,” he added. “In large trials, there are diseases that can arise by chance, but they must be independently reviewed,” said the company spokesman, emphasizing that there is still no certainty about the origin of the participant’s disease.
According to the health-related website StatNews, the case occurred with a participant in clinical trials in the UK and the decision to stop the trial was made with “great caution”. The company says it will try to analyze the case as soon as possible, so as not to delay the end of the trials.
[ad_2]
